The term directory may refer to:

Computing

---

• directory (file systems) — a way of organizing files and other directories
• directory (databases) — a large collection of information primarily for reading

History

---

• French Directory — a government in revolutionary France from 1795 to 1799

More on [ Directory ]

Pharma Industry / Biotech Industry News From Medical News Today

WHO, Wyeth Launch Trial In Africa To Test New River Blindness Drug
Fri, 03 Jul 2009 03:00:00 -0700
The WHO on Wednesday announced plans for a clinical trial to test a new drug that "could halve the treatment period for river blindness [or onchocerciasis], a disease that threatens 100 million people mostly in Africa," AFP/Dow Jones Newswires/CNN Money reports (7/1).
FDA Approves Multaq(R) For Patients With Atrial Fibrillation Or Atrial Flutter
Fri, 03 Jul 2009 02:00:00 -0700
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced that the U.S. Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets. Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve current management of their disease. Multaq(R) is the first drug approved in the United States that has shown a clinical benefit to reduce cardiovascular hospitalization in patients with AF/AFL.
Spanish Government Selects Novavax's VLP Technology For Comprehensive Flu Vaccine Solution In Spain
Fri, 03 Jul 2009 02:00:00 -0700
Novavax, Inc. (Nasdaq: NVAX) announced its initial agreement to license its proprietary, recombinant virus-like-particle (VLP) vaccine technology to ROVI Pharmaceuticals (Madrid: ROVI) of Spain.
Current Status Of The Development Programs Of New Indications And Formulations For Aricept(R) For Enhancing Patient Value
Fri, 03 Jul 2009 02:00:00 -0700
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") and Eisai Corporation of North America (Headquarters: Woodcliff Lake, NJ, Chairman and CEO Hajime Shimizu) are currently focusing on three clinical development programs for the company's major product Aricept(R) (donepezil hydrochloride tablets) to further contribute to patients with Alzheimer's disease. As progress in those programs has been made, Eisai announces the status as follows: 1.
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances The Effectiveness Of Standard Cancer Chemotherapy In Animal Models
Fri, 03 Jul 2009 01:00:00 -0700
Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT) announced that investigators of the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI), National Institutes of Health and Lixte reported that its novel compound, LB-1.2, enhances the effectiveness of two standard chemotherapy drugs in mouse models of human cancers. This research is being conducted under a Cooperative Research and Development Agreement between NINDS and Lixte.
Acura And King Receive FDA Complete Response Letter Regarding Acurox(R)
Fri, 03 Jul 2009 01:00:00 -0700
Acura Pharmaceuticals, Inc. (Nasdaq: ACUR) and King Pharmaceuticals, Inc. (NYSE: KG) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding the New Drug Application (NDA) for Acurox (oxycodone HC1, USP and niacin, USP) Tablets CII, an immediate release product intended for the relief of moderate-to-severe pain. The Complete Response Letter raises issues regarding the potential abuse deterrent benefits of Acurox(R).

The Seattle Times: Biotech


News on biotechnology pharmaceutical from BioPortfolio.com

Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances The Effectiveness Of Standard Cancer Chemotherap
MediLexicon:
KAI Pharmaceuticals Buys Patents from Progen
Individual.com:
KAI Pharmaceuticals Buys Patents from Progen
TradingMarkets:

The Economist: Biotechnology

Monitor: Third time lucky
Thu, 04 Jun 2009 11:53:53 -0000
Industrial biotech: A “third wave” of biotechnology is arriving. Will it be able to avoid a poor reception from the general public this time around?FOR a long time the public has perceived biotechnology to mean dangerous meddling with the genes in food crops. But biotechnology is of course about much more than transgenic food: it also encompasses the use of microbes to make pharmaceuticals, for example. The many benefits of the first wave of biotech products, in medicine, have unfortunately been overshadowed by the supposed risks of biotech’s second wave, in agriculture. Might its third wave—so-called industrial biotech, also known as “white biotech” or “green chemistry”—resolve biotech’s image problem?As with other forms of biotechnology, industrial biotech involves engineering biological molecules and microbes with desirable new properties. What is different is how they are then used: to replace chemical processes with biological ones. Whether this is to produce chemicals for other processes or to create products such as biopolymers with new properties, there is huge scope to harness biology to accomplish what previously needed big, dirty chemical factories, but in cleaner and greener ways. ...
Civil engineering: Filling in the cracks
Thu, 30 Apr 2009 11:37:50 -0000
How to preserve concrete with bacteriaCONCRETE is one of the most commonly used building materials. It is cheap, strong and easy to work with. But, as a short walk through any city centre will prove, it cracks easily. The cracking of concrete pavements is merely a nuisance, but cracks in roads, bridges and buildings are a hazard. A way of making concrete that healed such cracks spontaneously would thus be very welcome. And a team led by Henk Jonkers at the Delft University of Technology in the Netherlands may have come up with one.The way to stop concrete cracking is to bung up small cracks before they enlarge. That process of enlargement is caused by water getting into a crack, then freezing in cold weather and thus expanding. This freeze-thaw cycle, a common form of erosion of natural rocks, too, weakens a structure directly and also exposes steel reinforcing rods to water, causing them to rust. ...
North Carolina: Pipettes at the ready
Thu, 16 Apr 2009 11:57:43 -0000
The state helps engineer a biotech boomDURING a laboratory session at North Carolina State University in Raleigh, a dozen students gathered around a chromatography column. They were sending clarified lysate through an anion exchange, and some compared notes on the peculiar chemical smell of the classroom. “It’s like bad chicken noodle soup,” said one, wrinkling her nose. Others explained how they had ended up in the protective goggles and booties. Wrennie Edwards said that she had started her career in textiles, but now she was “transitioning” to a livelier field. Megan Crum explained that, growing up in Greensboro, she always wanted to be a vet. But once she got to university she realised that everyone wanted to be one. There were, she thought, more opportunities in biomanufacturing. Her father, who used to work in tobacco, was enthusiastic. ...

Subscribe to Biotechnology_and_Pharmaceuticals RSS feed